Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Stroobants

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Rheumatology (Oxford, England)|June 17, 1999
New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomographyD Blockmans, A Maes, S Stroobants, et al.
Science Robotics|May 15, 2024
Fully neuromorphic vision and control for autonomous drone flightF Paredes-Vallés, J J Hagenaars, J Dupeyroux, et al.
Melanoma Research|October 24, 2002
18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impactM Stas, S Stroobants, P Dupont, et al.
Rheumatology (Oxford, England)|June 3, 2008
Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritisD Blockmans, W Coudyzer, S Vanderschueren, et al.
British Journal of Haematology|November 13, 2001
Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?K Spaepen, S Stroobants, P Dupont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancerP Flamen, S Stroobants, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphomaK Spaepen, S Stroobants, P Dupont, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2001
Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET)P Flamen, O S Hoekstra, F Homans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?K Spaepen, S Stroobants, P Dupont, et al.
Lancet (London, England)|November 14, 2001
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyA T van Oosterom, I Judson, J Verweij, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Rheumatology (Oxford, England)|June 17, 1999
New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomographyD Blockmans, A Maes, S Stroobants, et al.
Science Robotics|May 15, 2024
Fully neuromorphic vision and control for autonomous drone flightF Paredes-Vallés, J J Hagenaars, J Dupeyroux, et al.
Melanoma Research|October 24, 2002
18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impactM Stas, S Stroobants, P Dupont, et al.
Rheumatology (Oxford, England)|June 3, 2008
Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritisD Blockmans, W Coudyzer, S Vanderschueren, et al.
British Journal of Haematology|November 13, 2001
Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?K Spaepen, S Stroobants, P Dupont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancerP Flamen, S Stroobants, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphomaK Spaepen, S Stroobants, P Dupont, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2001
Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET)P Flamen, O S Hoekstra, F Homans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?K Spaepen, S Stroobants, P Dupont, et al.
Lancet (London, England)|November 14, 2001
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyA T van Oosterom, I Judson, J Verweij, et al.
Pageof 4